China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SZSE:000999
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
EPS (Diluted)
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SZSE:000999
|
EPS (Diluted)
¥2
|
CAGR 3-Years
-6%
|
CAGR 5-Years
3%
|
CAGR 10-Years
11%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
EPS (Diluted)
¥0
|
CAGR 3-Years
18%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
EPS (Diluted)
¥5
|
CAGR 3-Years
9%
|
CAGR 5-Years
18%
|
CAGR 10-Years
24%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
EPS (Diluted)
¥1
|
CAGR 3-Years
12%
|
CAGR 5-Years
4%
|
CAGR 10-Years
15%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
EPS (Diluted)
¥2
|
CAGR 3-Years
19%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
1%
|
|
|
C
|
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
|
EPS (Diluted)
¥0
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
Glance View
In the intricate landscape of China's healthcare sector, China Resources Sanjiu Medical & Pharmaceutical Co Ltd stands as a significant player, weaving its extensive roots in both traditional and modern medicine. Emerging from the fusion of innovation and heritage, the company operates under the wing of China Resources, a state-owned conglomerate. This affiliation affords it a robust platform to traverse the dual path of pharmaceutical manufacturing and healthcare services. The company primarily engages in the development, production, and sale of a diverse range of pharmaceutical products, from essential medicines to over-the-counter dietary supplements. These offerings include both Western-style pharmaceuticals and traditional Chinese medicines, such as its widely recognized "999" branded cold medicines, allowing the company to leverage its expertise in a market with growing demand for holistic health solutions. China Resources Sanjiu generates its revenue through multiple channels, capitalizing on both domestic and international market opportunities. By integrating research and development with an efficient distribution network, the company ensures that its products reach a broad consumer base. In recent years, the company has focused on enhancing its research capabilities, investing heavily in developing innovative drugs that address prevalent health challenges. Sales of their proprietary and branded products are supported by strategic marketing initiatives, which highlight Sanjiu's commitment to quality and efficacy. Furthermore, the company's synergy with its parent organization facilitates expansions and strategic partnerships, reinforcing its competitive advantage in an industry marked by rapid evolution and stringent regulatory landscapes. With a foothold in both retail and institutional markets, China Resources Sanjiu Medical & Pharmaceutical Co Ltd continues to play a pivotal role in enhancing access to healthcare across China and beyond.
See Also
What is China Resources Sanjiu Medical & Pharmaceutical Co Ltd's EPS (Diluted)?
EPS (Diluted)
2.7
CNY
Based on the financial report for Sep 30, 2024, China Resources Sanjiu Medical & Pharmaceutical Co Ltd's EPS (Diluted) amounts to 2.7 CNY.
What is China Resources Sanjiu Medical & Pharmaceutical Co Ltd's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
11%
Over the last year, the EPS (Diluted) growth was 19%. The average annual EPS (Diluted) growth rates for China Resources Sanjiu Medical & Pharmaceutical Co Ltd have been -6% over the past three years , 3% over the past five years , and 11% over the past ten years .
You don't have any saved screeners yet